EGFR and neoplasm: Despite the success of targeted therapy in EGFR mutant NSCLC, the heterogeneous outcomes suggest that the effects may not depend solely on EGFR-driven cancer cells, but may also be associated with the local tumor immune microenvironment and antitumor T cell responses (12, 13).